Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

82. Brock malignancy risk calculator for pulmonary nodules: validation outside a lung cancer screening population

Brock malignancy risk calculator for pulmonary nodules: validation outside a lung cancer screening population 29777062 2018 05 19 1468-3296 2018 May 18 Thorax Thorax Brock malignancy risk calculator for pulmonary nodules: validation outside a lung cancer screening population. thoraxjnl-2017-211372 10.1136/thoraxjnl-2017-211372 To assess the performance of the Brock malignancy risk model for pulmonary nodules detected in routine clinical setting. In two academic centres in the Netherlands, we (...) established a list of patients aged ≥40 years who received a chest CT scan between 2004 and 2012, resulting in 16 850 and 23 454 eligible subjects. Subsequent diagnosis of lung cancer until the end of 2014 was established through linking with the National Cancer Registry. A nested case-control study was performed (ratio 1:3). Two observers used semiautomated software to annotate the nodules. The Brock model was separately validated on each data set using ROC analysis and compared with a solely size-based

EvidenceUpdates2018

83. Osimertinib (lung cancer) - Addendum to Commission A17-20

Osimertinib (lung cancer) - Addendum to Commission A17-20 1 Translation of addendum A17-47 Osimertinib (nicht kleinzelliges Lungenkarzinom) – Addendum zum Auftrag A17-20 (Version 1.0; Status: 28 September 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 28 September 2017 1.0 Commission: A17-47 Version: Status: IQWiG Reports – Commission No. A17-47 (...) Osimertinib (non-small cell lung cancer) – Addendum to Commission A17-20 1 Addendum A17-47 Version 1.0 Osimertinib – Addendum to Commission A17-20 28 September 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Osimertinib (non-small cell lung cancer) – Addendum to Commission A17-20 Commissioning agency: Federal Joint Committee Commission awarded on: 12 September 2017 Internal Commission No.: A17

Institute for Quality and Efficiency in Healthcare (IQWiG)2018

84. Alectinib (non-small-cell lung cancer) - Addendum to commission A17-19

Alectinib (non-small-cell lung cancer) - Addendum to commission A17-19 1 Translation of addendum A17-44 Alectinib (nicht kleinzelliges Lungenkarzinom) – Addendum zum Auftrag A17-19 (Version 1.0; Status: 29 September 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 29 September 2017 1.0 Commission: A17-44 Version: Status: IQWiG Reports – Commission (...) No. A17-44 Alectinib (non-small cell lung cancer) – Addendum to Commission A17-19 1 Addendum A17-44 Version 1.0 Alectinib – Addendum to Commission A17-19 29 September 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Alectinib (non-small cell lung cancer) – Addendum to Commission A17-19 Commissioning agency: Federal Joint Committee Commission awarded on: 4 September 2017 Internal Commission

Institute for Quality and Efficiency in Healthcare (IQWiG)2018

85. Lung cancer

Lung cancer Autosynthesis - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button

Trip Evidence Maps2018

86. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer

Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer Crizotinib for treating R Crizotinib for treating ROS1-positiv OS1-positive e advanced non-small-cell lung cancer advanced non-small-cell lung cancer T echnology appraisal guidance Published: 4 July 2018 nice.org.uk/guidance/ta529 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 26Contents Contents 1

National Institute for Health and Clinical Excellence - Technology Appraisals2018

87. Atezolizumab (Tecentriq) for non?small cell lung cancer (NSCLC)

Atezolizumab (Tecentriq) for non?small cell lung cancer (NSCLC) Published 9 July 2018 1 atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq ® ) SMC No 1336/18 Roche Products Limited 8 June 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission assessed under (...) the end of life and orphan medicine process atezolizumab (Tecentriq ® ) is accepted for restricted use within NHS Scotland Indication under review: As monotherapy for the treatment of adult patients with locally advanced or metastatic non -small cell lung cancer (NSCLC) after prior chemotherapy. Patients with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK) -positive tumour mutations should also have received targeted therapy before receiving atezolizumab. SMC

Scottish Medicines Consortium2018

88. Palliative thoracic radiotherapy in lung cancer

Palliative thoracic radiotherapy in lung cancer Practical Radiation Oncology Email/Username: Password: Remember me Search Terms Search within Search Share this page: Copyright © 2018 Inc. All rights reserved. | | | | | | The content on this site is intended for health professionals. We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the . Advertisements on this site do not constitute a guarantee or endorsement by the journal

American Society for Radiation Oncology2018

89. Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases

Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases 29947170 2018 11 14 1759-7714 9 9 2018 Sep Thoracic cancer Thorac Cancer Effectiveness of temozolomide combined with whole brain radiotherapy for non-small cell lung cancer brain metastases. 1121-1128 10.1111/1759-7714.12795 We performed a retrospective analysis to compare the efficacy of whole brain radiotherapy (WBRT) combined with temozolomide (TMZ) versus WBRT alone (...) as first-line treatment for brain metastases (BM). Seventy-eight non-small cell lung cancer patients with BM were observed, including 45 patients who received WBRT plus TMZ (TMZ + WBRT) and 33 patients who received WBRT alone (WBRT). The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), objective response rate (ORR), and adverse events. The TMZ + WBRT arm achieved significant improvement in ORR (P = 0.0108) compared to the WBRT arm. PFS in the TMZ

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

90. Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer

Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer 30035160 2018 11 14 2331-4737 5 5-6 2018 May Oncoscience Oncoscience Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer. 124-125 10.18632/oncoscience.416 Seguin Laetitia L INSERM, U1081, CNRS, UMR7284, Institute for Research on Cancer and Aging of Nice (IRCAN), University of Nice Sophia Antipolis, Nice, France. Féral Chloé C INSERM, U1081, CNRS, UMR7284, Institute (...) for Research on Cancer and Aging of Nice (IRCAN), University of Nice Sophia Antipolis, Nice, France. eng Editorial 2018 06 23 United States Oncoscience 101636666 2331-4737 KRAS galectin-3 integrin lung cancer macropinocytosis CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 04 03 2018 04 05 2018 7 24 6 0 2018 7 24 6 0 2018 7 24 6 1 epublish 30035160 10.18632/oncoscience.416 416 PMC6049313 Cancer Immunol Res. 2017 Mar;5(3):182-190 28108630 Nat Cell Biol. 2014 May;16(5):457

Oncoscience2018 Full Text: Link to full Text with Trip Pro

91. Feasibility of an eight‐week outpatient‐based pulmonary rehabilitation program for advanced lung cancer patients undergoing cytotoxic chemotherapy in Korea

Feasibility of an eight‐week outpatient‐based pulmonary rehabilitation program for advanced lung cancer patients undergoing cytotoxic chemotherapy in Korea 29932301 2018 11 14 1759-7714 9 8 2018 Aug Thoracic cancer Thorac Cancer Feasibility of an eight-week outpatient-based pulmonary rehabilitation program for advanced lung cancer patients undergoing cytotoxic chemotherapy in Korea. 1069-1073 10.1111/1759-7714.12788 The scientific evidence supporting pulmonary rehabilitation (PR) for lung (...) cancer patients undergoing cytotoxic chemotherapy is accumulating; however, the feasibility of outpatient-based PR in these patients has not yet been evaluated in Korea. We conducted an eight-week outpatient-based PR feasibility study in a tertiary referral hospital setting. Patients with advanced lung cancer (non-small cell lung cancer IIIB-IV and small-cell lung cancer extensive disease) scheduled to undergo first-line cytotoxic chemotherapy underwent PR consisting of 60-minute sessions twice

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

92. DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer

DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer 29932513 2018 11 14 1759-7714 9 8 2018 Aug Thoracic cancer Thorac Cancer DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. 901-903 10.1111/1759-7714.12785 Zhu Zhongling Z Department of Clinical Pharmacology, Tianjin Medical (...) University Cancer Institute and Hospital, Tianjin, China. National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin, China. Chen Peng P National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin, China. Department of Thoracic Medical Oncology, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

93. P16 INK4a gene promoter methylation as a biomarker for the diagnosis of non‐small cell lung cancer: An updated meta‐analysis

P16 INK4a gene promoter methylation as a biomarker for the diagnosis of non‐small cell lung cancer: An updated meta‐analysis 29927090 2018 11 14 1759-7714 9 8 2018 Aug Thoracic cancer Thorac Cancer P16 INK4a gene promoter methylation as a biomarker for the diagnosis of non-small cell lung cancer: An updated meta-analysis. 1032-1040 10.1111/1759-7714.12783 This meta-analysis was conducted to investigate the diagnostic performance of P16 INK4a gene promoter methylation as a biomarker of non (...) -small cell lung cancer (NSCLC). Two reviewers independently searched the Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, and Chinese Biomedical Literature databases. Publications relevant to P16 INK4a gene promoter methylation in serum or bronchoalveolar fluid/sputum were screened and included in this meta-analysis. Pooled diagnostic sensitivity, specificity, and symmetric receiver operating characteristic curve were calculated. Twenty-six publications with 1768

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

94. Survival rates after lobectomy versus sublobar resection for early‐stage right middle lobe non‐small cell lung cancer

Survival rates after lobectomy versus sublobar resection for early‐stage right middle lobe non‐small cell lung cancer 29927089 2018 11 14 1759-7714 9 8 2018 Aug Thoracic cancer Thorac Cancer Survival rates after lobectomy versus sublobar resection for early-stage right middle lobe non-small cell lung cancer. 1026-1031 10.1111/1759-7714.12782 Lung cancer in the right middle lobe has a poorer prognosis than tumors located in other lobes. The optimal surgical procedure for early-stage non (...) -small cell lung cancer (NSCLC) in the right middle lobe has not yet been elucidated. The aim of this study was to compare survival rates after lobectomy and sublobar resection for early-stage right middle lobe NSCLC. Patients who underwent lobectomy or sublobar resection for stage IA right middle lobe NSCLC tumors ≤ 2 cm between 2004 and 2014 were identified from the Surveillance, Epidemiology and End Results database of 18 registries. Cox regression model analysis was used to evaluate

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

95. Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non‐small‐cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors

Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non‐small‐cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors 29924498 2018 11 14 1759-7714 9 8 2018 Aug Thoracic cancer Thorac Cancer Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors. 1012-1017 10.1111/1759-7714.12779 Although (...) patients with EGFR-mutant non-small-cell lung cancer (NSCLC) benefit from treatment with EGFR-tyrosine kinase inhibitors (TKIs), outcomes are limited by the eventual development of acquired resistance. We conducted a retrospective study to evaluate the efficacy and feasibility of EGFR-TKI therapy beyond focal progression, associated with microwave ablation. Patients with metastatic EGFR-mutant NSCLC treated with EGFR-TKIs at our institutions from May 2012 to December 2017 were identified. Patients

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

96. Comparing first‐line treatment patterns and clinical outcomes of patients with pan‐negative advanced non‐squamous non‐small cell lung cancer

Comparing first‐line treatment patterns and clinical outcomes of patients with pan‐negative advanced non‐squamous non‐small cell lung cancer 29917332 2018 11 14 1759-7714 9 8 2018 Aug Thoracic cancer Thorac Cancer Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer. 1005-1011 10.1111/1759-7714.12777 Platinum-based chemotherapy is the standard first-line treatment for patients with advanced pan (...) -negative non-squamous (non-Sq) non-small cell lung cancer (NSCLC). However, it is unknown which chemotherapy regimen confers the greatest benefit in such patients. This study explored which chemotherapy regimens were advantageous in non-Sq NSCLC patients. A retrospective study was conducted on 114 patients with advanced non-Sq NSCLC using platinum-based chemotherapy in a first-line setting between January 2013 and December 2015. The study evaluated the most common first-line regimens including

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

97. Efficacy of repeated surgery is superior to that of non‐surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer

Efficacy of repeated surgery is superior to that of non‐surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer 29917320 2018 11 14 1759-7714 9 8 2018 Aug Thoracic cancer Thorac Cancer Efficacy of repeated surgery is superior to that of non-surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer. 1062-1068 10.1111/1759-7714.12790 The current study aimed to determine the oncological efficacy and surgical safety (...) of multiple pulmonary resections (MPRs) after prior curative surgery for local regional recurrent or second primary lung cancers. All cases of lung cancer included in our prospective database between January 2000 and July 2015 were retrospectively reviewed. The oncological efficacy endpoints for synchronous and metachronous MPR were five-year overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) rates after the second surgery. The surgical safety endpoints were

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

98. DNA repair capacity correlates with standardized uptake values from 18F-fluorodeoxyglucose positron emission tomography/CT in patients with advanced non–small-cell lung cancer

DNA repair capacity correlates with standardized uptake values from 18F-fluorodeoxyglucose positron emission tomography/CT in patients with advanced non–small-cell lung cancer 29988954 2018 11 14 2589-0514 4 2 2018 Jun Chronic diseases and translational medicine Chronic Dis Transl Med DNA repair capacity correlates with standardized uptake values from 18 F-fluorodeoxyglucose positron emission tomography/CT in patients with advanced non-small-cell lung cancer. 109-116 10.1016/j.cdtm (...) .2018.05.003 The DNA repair capacity (DRC) of tumor cells is an important contributor to resistance to radiation and platinum-based drugs. Because DRC may be affected by tumor cell metabolism, we measured DRC in lymphocytes from patients with non-small-cell lung cancer (NSCLC) and compared the findings with the maximum standardized uptake value (SUV max ) on 18 F-fluorodeoxyglucose positron emission tomography (FDG PET) after (chemo)radiation therapy. This study included 151 patients with stage IA-IV NSCLC

Chronic diseases and translational medicine2018 Full Text: Link to full Text with Trip Pro

99. Long non‐coding RNA OIP5‐AS1 promotes proliferation of lung cancer cells and leads to poor prognosis by targeting miR‐378a‐3p

Long non‐coding RNA OIP5‐AS1 promotes proliferation of lung cancer cells and leads to poor prognosis by targeting miR‐378a‐3p 29897167 2018 11 14 1759-7714 9 8 2018 Aug Thoracic cancer Thorac Cancer Long non-coding RNA OIP5-AS1 promotes proliferation of lung cancer cells and leads to poor prognosis by targeting miR-378a-3p. 939-949 10.1111/1759-7714.12767 The antisense of the OIP5-AS1 gene is a long non-coding RNA (lncRNA) that is reported to be upregulated and promotes cell (...) proliferation in multiple human cancers; however, its function in lung cancer is unknown. We investigated the regulatory function and underlying mechanisms of OIP5-AS1 in lung cancer. OIP5-AS1 and microRNA (miR)-378a-3p expression were assayed by quantitative real-time PCR, and proliferation-related protein expression was measured by Western blotting. Cell viability was detected using methyl thiazolyl tetrazolium assay. Luciferase reporter assay and RNA immunoprecipitation were used to detect the direct

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

100. Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive‐disease small cell lung cancer in the elderly and patients with poor performance status

Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive‐disease small cell lung cancer in the elderly and patients with poor performance status 29870153 2018 11 14 1759-7714 9 8 2018 Aug Thoracic cancer Thorac Cancer Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status. 967-973 10.1111/1759-7714.12772 Carboplatin plus etoposide (CE) is a standard (...) treatment for elderly patients with extensive-disease small cell lung cancer (ED-SCLC). However, amrubicin monotherapy (AMR) may be a feasible alternative. We compared the efficacies and safety profiles of CE and AMR for ED-SCLC in elderly patients and chemotherapy-naive patients with poor performance status (PS). The records of SCLC patients who received CE or AMR as first-line chemotherapy were retrospectively reviewed and their treatment outcomes evaluated. Eighty-four patients (median age 72 years

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro